Ensign Peak Advisors
RXRX icon

Ensign Peak Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Ensign Peak Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.8K Hold
29,264
– – ﹤0.01% 1593
2025
Q4 		$120K Sell
29,264
-380,672
-93% -$1.89M ﹤0.01% 1527
2025
Q3 		$2M Sell
409,936
-350
-0.1% -$1.84K ﹤0.01% 800
2025
Q2 		$2.08M Hold
410,286
– – ﹤0.01% 892
2025
Q1 		$2.17M Hold
410,286
– – ﹤0.01% 870
2024
Q4 		$2.77M Buy
410,286
+1,300
+0.3% +$8.74K ﹤0.01% 815
2024
Q3 		$2.7M Hold
408,986
– – ﹤0.01% 827
2024
Q2 		$3.07M Buy
408,986
+10,050
+3% +$87.7K 0.01% 765
2024
Q1 		$3.98M Buy
398,936
+11,421
+3% +$127K 0.01% 695
2023
Q4 		$3.82M Buy
387,515
+172,545
+80% +$1.23M 0.01% 697
2023
Q3 		$1.64M Buy
214,970
+45,750
+27% +$456K ﹤0.01% 902
2023
Q2 		$1.26M Buy
+169,220
New +$1.18M ﹤0.01% 1081
2022
Q4 		– Sell
-15,470
Closed -$165K – 2143
2022
Q3 		$165K Hold
15,470
– – ﹤0.01% 1943
2022
Q2 		$126K Hold
15,470
– – ﹤0.01% 1917
2022
Q1 		$111K Hold
15,470
– – ﹤0.01% 2010
2021
Q4 		$265K Buy
+15,470
New +$291K ﹤0.01% 1855

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ensign Peak Advisors's RXRX Position: Q1 2026 in Review

Ensign Peak Advisors held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 29,264 shares worth $89.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

Ensign Peak Advisors first reported a position in RXRX in Q4 2021 and has held it in 16 quarters since. The position peaked at $3.98M in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Ensign Peak Advisors held 29,264 shares of Recursion Pharmaceuticals worth $89.8K as of Q1 2026.
  • Ensign Peak Advisors left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #1593 holding.
  • Ensign Peak Advisors first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 16 quarters since.
  • Ensign Peak Advisors's Recursion Pharmaceuticals position peaked at $3.98M in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.